Interview with Rhenu Bhuller, Vice President of Health Care for Asia Pacific,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Address: 100 Beach Road
#29-01/11, Shaw Tower
Singapore 189 702
Tel: +65 68900999
Web: http://www.frost.com/c/10024/home.do
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
Through Frost & Sullivan’s Healthcare Growth Partnership Services program, clients receive a continuous flow of actionable market, technical, and econometric research, along with applications for growth. They continuously monitor the following Healthcare market sectors: pharmaceuticals and biotechnology, drug discovery technologies, clinical diagnostics, healthcare IT, medical imaging, and medical devices, and provides local expertise along with a global perspective.
Consultant
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to…
Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing…
See our Cookie Privacy Policy Here
